Table 1
Open in new tab

Baseline characteristics

SPVI group (n = 42)Centre 1 HSR (n = 22)Centre 2 MST (n = 20)P-value
Age, years55 ± 1057 ± 854 ± 120.099
Male, n (%)32 (76%)19 (86%)13 (65%)0.152
Median AF history, months (range)24 [3–200]24 [12–200]19 [3–144]0.165
Previous transcatheter PVI9 (21%)7 (32%)2 (10%)0.135
EHRA-score0.769
 II, n (%)20 (48%)10 (45%)10 (50%)
 III, n (%)22 (52%)12 (55%)10 (50%)
NYHA-score0.945
 II, n (%)40 (95%)21 (95%)19 (95%)
 III, n (%)2 (5%)1 (5%)1 (5%)
CHA2DS2-VASC0.176
 0, n (%)18 (42%)10 (45%)8 (40%)
 1, n (%)16 (37%)8 (36%)8 (40%)
 ≥2, n (%)8 (19%)4 (18%)4 (20%)
BMI (kg/m²)27 ± 426 ± 327 ± 40.489
Hypertension, n (%)14 (33%)8 (43%)6 (30%)0.750
Echocardiographic findings
 LV ejection fraction (mm)58 ± 659 ± 356 ± 80.240
 LA parasternal diameter (mm)42 ± 543 ± 541 ± 50.658
SPVI group (n = 42)Centre 1 HSR (n = 22)Centre 2 MST (n = 20)P-value
Age, years55 ± 1057 ± 854 ± 120.099
Male, n (%)32 (76%)19 (86%)13 (65%)0.152
Median AF history, months (range)24 [3–200]24 [12–200]19 [3–144]0.165
Previous transcatheter PVI9 (21%)7 (32%)2 (10%)0.135
EHRA-score0.769
 II, n (%)20 (48%)10 (45%)10 (50%)
 III, n (%)22 (52%)12 (55%)10 (50%)
NYHA-score0.945
 II, n (%)40 (95%)21 (95%)19 (95%)
 III, n (%)2 (5%)1 (5%)1 (5%)
CHA2DS2-VASC0.176
 0, n (%)18 (42%)10 (45%)8 (40%)
 1, n (%)16 (37%)8 (36%)8 (40%)
 ≥2, n (%)8 (19%)4 (18%)4 (20%)
BMI (kg/m²)27 ± 426 ± 327 ± 40.489
Hypertension, n (%)14 (33%)8 (43%)6 (30%)0.750
Echocardiographic findings
 LV ejection fraction (mm)58 ± 659 ± 356 ± 80.240
 LA parasternal diameter (mm)42 ± 543 ± 541 ± 50.658

AAD, anti-arrhythmic drugs; TEE, thrombo-embolic; LA, left atrium.

Table 1
Open in new tab

Baseline characteristics

SPVI group (n = 42)Centre 1 HSR (n = 22)Centre 2 MST (n = 20)P-value
Age, years55 ± 1057 ± 854 ± 120.099
Male, n (%)32 (76%)19 (86%)13 (65%)0.152
Median AF history, months (range)24 [3–200]24 [12–200]19 [3–144]0.165
Previous transcatheter PVI9 (21%)7 (32%)2 (10%)0.135
EHRA-score0.769
 II, n (%)20 (48%)10 (45%)10 (50%)
 III, n (%)22 (52%)12 (55%)10 (50%)
NYHA-score0.945
 II, n (%)40 (95%)21 (95%)19 (95%)
 III, n (%)2 (5%)1 (5%)1 (5%)
CHA2DS2-VASC0.176
 0, n (%)18 (42%)10 (45%)8 (40%)
 1, n (%)16 (37%)8 (36%)8 (40%)
 ≥2, n (%)8 (19%)4 (18%)4 (20%)
BMI (kg/m²)27 ± 426 ± 327 ± 40.489
Hypertension, n (%)14 (33%)8 (43%)6 (30%)0.750
Echocardiographic findings
 LV ejection fraction (mm)58 ± 659 ± 356 ± 80.240
 LA parasternal diameter (mm)42 ± 543 ± 541 ± 50.658
SPVI group (n = 42)Centre 1 HSR (n = 22)Centre 2 MST (n = 20)P-value
Age, years55 ± 1057 ± 854 ± 120.099
Male, n (%)32 (76%)19 (86%)13 (65%)0.152
Median AF history, months (range)24 [3–200]24 [12–200]19 [3–144]0.165
Previous transcatheter PVI9 (21%)7 (32%)2 (10%)0.135
EHRA-score0.769
 II, n (%)20 (48%)10 (45%)10 (50%)
 III, n (%)22 (52%)12 (55%)10 (50%)
NYHA-score0.945
 II, n (%)40 (95%)21 (95%)19 (95%)
 III, n (%)2 (5%)1 (5%)1 (5%)
CHA2DS2-VASC0.176
 0, n (%)18 (42%)10 (45%)8 (40%)
 1, n (%)16 (37%)8 (36%)8 (40%)
 ≥2, n (%)8 (19%)4 (18%)4 (20%)
BMI (kg/m²)27 ± 426 ± 327 ± 40.489
Hypertension, n (%)14 (33%)8 (43%)6 (30%)0.750
Echocardiographic findings
 LV ejection fraction (mm)58 ± 659 ± 356 ± 80.240
 LA parasternal diameter (mm)42 ± 543 ± 541 ± 50.658

AAD, anti-arrhythmic drugs; TEE, thrombo-embolic; LA, left atrium.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close